cangrelor tetrasodium
|
|
|
- CAS-Nr.
- 163706-36-3
- Englisch Name:
- cangrelor tetrasodium
- Synonyma:
- CS-1027;angrelor tetrasodium;cangrelor tetrasodium;Cangrelor Tetrasodium Salt;AR-C 69931 Tetrasodium Salt;cangrelor tetrasodium, 10 mM in DMSO;Cangrelor tetrasodium salt >=98% (HPLC);tetrasodium 5'-O-[({[dichloro(phosphonato)methyl]phosphinato...;N-[2-(Methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]adenosine-5'-O-(β,γ-dichloromethylene)triphosphate tetrasodium salt;tetrasodium 5'-O-[({[dichloro(phosphonato)methyl]phosphinato}oxy)phosphinato]-N-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]adenosine
- CBNumber:
- CB43040494
- Summenformel:
- C17H21Cl2F3N5Na4O12P3S2
- Molgewicht:
- 864.2865126
- MOL-Datei:
- 163706-36-3.mol
|
cangrelor tetrasodium Eigenschaften
- storage temp.
- 4°C, away from moisture and light
- L?slichkeit
- DMSO:100.0(Max Conc. mg/mL);115.7(Max Conc. mM)
- Aggregatzustand
- A solid
- Farbe
- White to off-white
- Wasserl?slichkeit
- Soluble to 100 mM in water
- InChIKey
- COWWROCHWNGJHQ-OPKBHZIBSA-J
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
cangrelor tetrasodium Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Cangrelor
tetrasodium is a direct purinergic platelet receptor (P2Y12)
inhibitor that blocks ADP-induced platelet activation and
aggregation. The drug, which was developed by The
Medicine Company, binds reversibly to the P2Y12 receptor,
preventing further signaling and platelet activation. Cangrelor,
which was approved in June 2015 by the FDA, is indicated as
an adjunct to percutaneous coronary intervention for reducing
the risk of periprocedural myocardial infarction, repeat
coronary revascularization, and stent thrombosis in patients
who have not been treated with a P2Y12 platelet inhibitor and
are not being given a glycoprotein IIb/IIIa inhibitor. The
most common side effect observed with the drug was
bleeding.
Verwenden
Antiplatelet agent.
Definition
ChEBI: An organic sodium salt that is the tetrasodium salt of cangrelor. Used as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.
cangrelor tetrasodium Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
cangrelor tetrasodium Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 132)Lieferanten
163706-36-3()Verwandte Suche:
Natriumcalciumedetat
Natriumferedetat
Dinatrium-[[N,N'-ethylenbis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',ON,ON']magnesat(2-)
Tetranatrium-[29H,31H-phthalocyanintetrasulfonato(6-)-N29,N30,N31,N32]cuprat(4-)
- cangrelor tetrasodium
- angrelor tetrasodium
- CS-1027
- N-[2-(Methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]adenosine-5'-O-(β,γ-dichloromethylene)triphosphate tetrasodium salt
- Cangrelor Tetrasodium Salt
- tetrasodium 5'-O-[({[dichloro(phosphonato)methyl]phosphinato}oxy)phosphinato]-N-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]adenosine
- Cangrelor tetrasodium salt >=98% (HPLC)
- AR-C 69931 Tetrasodium Salt
- (Dichloro((((((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-((2-(methylthio)ethyl)amino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)methyl)phosphonic acid tetrasodium salt
- tetrasodium 5'-O-[({[dichloro(phosphonato)methyl]phosphinato...
- cangrelor tetrasodium, 10 mM in DMSO
- 163706-36-3
- C17H21Cl2F3N5Na4O12P3S2
- C17H21Cl2F3N5O12P3S24Na
